



Review

A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women

Flor M. Munoz^{a,*,1}, Beate Kampmann^{b,2}, Andy Stergachis^{c,3}, Manu Chaudhary^{d,4}, Clare L. Cutland^{e,5}, Asma Khalil^{f,6}, Angela Gentile^{g,7}, Christine E. Jones^{h,8}, Helen Marshall^{i,9}, Esperanca Sevene^{j,10}, Delese Mimi Darko^{k,11}, Geeta Swamy^{l,12}, Terri B. Hyde^{m,13}, Gerald Voss^{n,14}, Ajoke Sobanjo-Ter Muelen^{o,15}

^a Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

^b Charité – Universitätsmedizin Berlin, Berlin, Germany and LSTMH, London, UK

^c School of Pharmacy, University of Washington, Seattle, WA, and School of Public Health, University of Washington, Seattle, WA, USA

^d Department of Infectious Diseases, Rainbow Children's Hospital, Bangalore, India

^e Wits African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

^f Fetal Medicine Unit, St George's University of London, London, UK

^g Epidemiology Department, Ricardo Gutierrez Children Hospital, University of Buenos Aires, Argentina

^h Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, and NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS, Southampton, UK

ⁱ Women's and Children's Health Network, and The University of Adelaide, Adelaide, SA, Australia

^j Department of Physiological Science, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique

^k Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria

^l Department of Obstetrics & Gynecology, Duke University, Durham, NC, USA

^m Centers for Disease Control and Prevention, Atlanta, GA, USA

ⁿ Coalition for Epidemic Preparedness Innovations (CEPI) London, UK

^o Department of Global Health, University of Washington, Seattle, Washington, USA



ARTICLE INFO

Keywords:

Maternal vaccination

Vaccines

Safety surveillance

ABSTRACT

Vaccination during pregnancy provides effective protection against pathogens that increase the risk of maternal and infant morbidity and mortality for mothers and their infants. The SARS-CoV-2 pandemic demonstrated the need for the inclusion of pregnant and breast-feeding women in research and development of vaccines for emerging pathogens, such as Ebola, Zika, Lassa fever, Chikungunya, and influenza virus of pandemic potential.

* Corresponding author at: Molecular Virology and Microbiology, Baylor College of Medicine, 1102 Bates, Suite 1150, Houston, TX 7703, USA.

E-mail addresses: florm@bcm.edu (F.M. Munoz), Beate.Kampmann@lshtm.ac.uk (B. Kampmann), stergach@uw.edu (A. Stergachis), Clare.Cutland@wits.ac.za (C.L. Cutland), akhalil@sgul.ac.uk (A. Khalil), C.E.Jones@soton.ac.uk (C.E. Jones), helen.marshall@adelaide.edu.au (H. Marshall), geeta.swamy@duke.edu (G. Swamy), thyde@cdc.gov (T.B. Hyde), gerald.voss@cepi.net (G. Voss).

¹ 0000-0002-0457-7689.

² 0000-0002-6546-4709.

³ 0000-0003-0057-6627.

⁴ 0000-0003-1822-8276.

⁵ 0000-0001-8250-8307.

⁶ 0000-0003-2802-7670.

⁷ 0000-0002-1072-7700.

⁸ 0000-0003-1523-2368.

⁹ 0000-0003-2521-5166.

¹⁰ 0000-0001-9025-4052.

¹¹ 0000-0003-0229-9838.

¹² 0000-0001-5092-6993.

¹³ 0000-0002-4079-0380.

¹⁴ 0000-0002-1984-5121.

¹⁵ 0000-0002-5372-4630.

<https://doi.org/10.1016/j.vaccine.2025.127513>

Received 30 August 2024; Received in revised form 3 July 2025; Accepted 11 July 2025

Available online 18 July 2025

0264-410X/© 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

Benefit-risk
Template
Pandemic
Emerging pathogens

The COVID-19 Vaccines Global Access (COVAX) Maternal Immunization Working Group (MIWG), in collaboration with the Coalition for Epidemic Preparedness Innovation and the Safety Platform for Emergency Vaccines (CEPI-SPEAC) developed a standardized template with key considerations to guide the assessment of vaccines against emerging pathogens in pregnant and breast-feeding women. The aim of this tool is to enable key stakeholders to perform an early structured assessment of the overall potential benefit and risk for maternal immunization against an emerging pathogen. It can also be used to support risk management and pharmacovigilance planning, communication strategies, policy development, and acceptance of vaccination during pregnancy in future pandemics.

1. Introduction

Globally, an estimated 213 million pregnancies occur annually [1]. Women represent 71 % of the global workforce of the health sector and this percentage is likely to be higher in low- and middle-income countries (LMICs) [2–4]. It is estimated that at any given time in the United States (US) there are over 300,000 women of child-bearing age, i.e., 15–49 years old in the healthcare workforce, and in the WHO regions, 67 % of the healthcare workforce are female, particularly in the nursing and midwifery workforce [5,6]. Healthcare-related occupations are critical during an epidemic or pandemic responses and should, therefore, be prioritized for vaccine allocation, as was seen during the COVID-19 pandemic [7]. In addition, women often have jobs that are associated with high risk of exposure, such as childcare providers, teachers, public-facing and hospitality workers, and caregivers. The COVID-19 pandemic highlighted the urgent need for guidance on immunization strategies for pregnant and breast-feeding women, especially for those who rely on employment in these high-risk occupations.

In addition, pregnant women and their fetuses are at increased risk for severe disease and death from SARS-CoV-2 and other respiratory and emerging pathogens, often in association with pregnancy physiology [8–12]. Older pregnant women (36–44 years), and those who have underlying medical conditions, such as obesity, gestational diabetes or hypertension, might be at higher risk of severe disease, similar to the higher risks seen in older individuals and those with underlying medical conditions in the general population [13–16]. Data from high income countries (HICs) suggest that adverse birth outcomes, such as preterm delivery and stillbirth, are more common among pregnant women infected with SARS-CoV-2, while in endemic areas, pregnant women infected with Ebola and Lassa fever also have higher risk of these outcomes compared with non-infected individuals [13,16–20].

Healthcare access disparities affect pregnant women worldwide. Studies from the US and the United Kingdom reported that Black and Hispanic pregnant women were at higher risk of severe disease and hospitalization than nonpregnant women [12,18]. Limited pregnancy-specific data are available from LMICs, mainly due to a lack of data collection infrastructures. The results from a meta-analysis showed that the overall risk of adverse pregnancy outcomes was higher in LMICs than in HICs (OR 2.4) [21]. COVID-19-related abortion (OR 6.2), stillbirths (OR 2.0), and maternal death (OR 7.8) were more common in LMICs compared with HIC [21]. Additional data will be needed to inform local decision-making and improve acceptance of vaccines for pregnant and breast-feeding women.

2. Vaccines against emerging pathogen for pregnant women

Vaccines for pregnant women are one of the most important public health measures undertaken globally to reduce the burden of disease in mothers and infants from tetanus, pertussis and seasonal influenza. During previous pandemics caused by respiratory pathogens, such as influenza A/H1N1pdm09, infection in pregnant women was associated with an increased risk for severe disease and hospitalization, and pregnant women have subsequently been prioritized for immunization [22–24]. Ebola vaccines are being evaluated in pregnant women in epidemic regions in West Africa, with observational studies evaluating

vaccines since 2016 and interventional studies since 2020 [25,26].

Various organizations, including the U.S. National Academy of Medicine (NAM), the American College of Obstetrics and Gynecology (ACOG), the Pregnancy Research Ethics for Vaccines, Epidemics, and new Technologies (PREVENT) group, and the World Health Organization (WHO), supported the position that pregnant and breast-feeding women are a priority population that must not be excluded from COVID-19 vaccine allocation strategies [23,27–30]. Reports from observational cohort studies conducted in countries that included pregnant women early in their COVID-19 vaccine implementation strategies, such as Israel, demonstrated a significantly lower risk of SARS-CoV-2 infection among vaccinated pregnant women compared with unvaccinated pregnant women (adjusted hazard ratio 0.22, 95 % CI: 0.11–0.43) [31].

The Council for International Organizations of Medical Sciences (CIOMS) and the United Nations AIDS/World Health Organization guidelines, in 2002 and 2005, respectively, encouraged the inclusion of pregnant women in clinical studies [32,33]. More recently, the U.S. Food and Drug Administration (FDA) draft guidance for the pharmaceutical industry also supported for the inclusion of pregnant women in clinical trials [34]. Exclusion of pregnant women from clinical trials can lead to a lack of data that is needed to make informed decisions about the potential benefits and risks of medications and vaccines administered during pregnancy.

It has been reported that recruitment and retention of pregnant women in clinical trials is challenging [35–37]. Although pregnant women have been reported to be willing to participate in clinical research, they are more willing to participate in observational or retrospective studies or life-style interventional studies than randomized trials, particularly those including placebo groups [38,39]. Strategies for encouraging pregnant women to participate in clinical trials should be evaluated [39].

In 2020 in their guidance for developing and licensing COVID-19 vaccines FDA encouraged vaccine manufacturers to collect and consider “data that might support inclusion of pregnant women and women of childbearing potential who are not actively avoiding pregnancy in pre-licensure clinical trials” because the use of “COVID-19 preventive vaccines during pregnancy and in women of childbearing potential will be an important consideration for vaccination programs” [40]. However, the guidance did not specify what data should be collected.

3. The COVAX-CEPI-SPEAC maternal immunization working group

In April 2020, in response to the COVID-19 pandemic, a global collaboration, the Access to COVID-19 Tools (ACT) Accelerator, was launched to facilitate the development, production of COVID-19 tests, treatments, and vaccines, and to ensure equitable access [41]. The ACT Accelerator’s SARS-CoV-2 vaccine research, development and manufacturing workstream included a Clinical Development and Operations Specialized Working Team (SWAT) to identify tools and provide support for vaccine developers to facilitate COVID-19 vaccine licensure. The SWAT team established the COVID-19 Vaccines Global Access and Coalition of Epidemic Preparedness Innovation (COVAX-CEPI) Maternal Immunization Working Group (MIWG) in August 2020 to address the

needs of pregnant and breast-feeding women during the COVID-19 pandemic. In 2022 the group integrated into the Special Populations MIWG of the Safety Platform for Emergency Vaccines (SPEAC)-Brighton Collaboration project supported by CEPI. The members of the MIWG included professionals with expertise in various aspects of maternal immunization that represented diverse backgrounds, organizations, and geographical settings (Appendix 1).

The principal goal of the MIWG is to facilitate access to vaccine candidates that are suitable for use in pregnant and breast-feeding women by:

- 1) identifying approaches for the evaluation of vaccine candidates from pre-licensure clinical trials to the post-licensure period, using COVID-19 vaccines as a model;
- 2) creating an evaluation framework for vaccine candidates for use in this population; and
- 3) identifying the data and studies that are needed to close the gap in the availability and access to safe and effective vaccination and prevention strategies for these women.

Three work stream groups were set up to cover issues relevant to the inclusion of pregnant women in the vaccine development pathway, from the pre-clinical phase through to the post-licensure phase. During weekly or bi-weekly meetings, work stream representatives shared their findings with the group and identified areas of consensus to refine and address their key questions. The groups also solicited input from external subject matter experts as needed. Ethics and regulatory advisors in the group reviewed work stream discussions and outputs and provided guidance.

4. Description of proposed evaluation framework for vaccine development for use in pregnant and breast-feeding women

The MIWG developed key questions to be used as an evaluation framework for all stages of vaccine development for different vaccine platforms for use in pregnant and breast-feeding women, including in future pandemics or outbreaks (Table 1). The framework was designed to guide the evaluation of candidate vaccines rather to be used as a mandatory checklist. It is not intended to be either exhaustive or required in all instances and should not hinder the development of clinical trial protocols.

The key questions table is divided into sections addressing general topics for the evaluation of candidate vaccines in pregnant and breast-feeding women (Table 1). The questions were developed to be used as a guide for the assessment of vaccines. It is recommended to start with the questions in Section A and work through the sections sequentially to Section E. These questions serve as a guide and it is possible that not all questions will be completely answered, and, in some situations, some may not even be addressed if data is not available (e.g. in LMIC). The sources of information, as well as the date of the data review should be documented for each answer. These sources may include publications, studies in progress, guidance documents, policy statements, vaccine recommendations, and others, as pertinent. The key questions may be readdressed, as new information emerges.

The questions in section A establish the impact and burden of the disease or pathogen in this population, as well as in the infants' fetal and neonatal periods. Those in section B aims to seek product or platform specific information. Some of this information will not be unique to this population, but any data from adult populations, particularly women of childbearing age, will be informative. It is recommended to use the BRAVATO (Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology) templates for specific vaccine constructs to gather product-specific information, and to complete these with additional pregnancy-related questions provided in the questionnaire [42].

The questions in section C aim to collect information relevant to all vaccines that can be considered for pregnant and breast-feeding women,

irrespective of the specific product or vaccine platform. Some of the questions may need to be fully addressed before vaccine studies or implementation are possible. It is recommended to seek relevant regulatory agency guidance to determine which items need to be addressed at each phase of vaccine development.

The questions in section D seek information for the safety evaluation of all vaccines to be used in pregnant and breast-feeding women, both during clinical trials as well as post-licensure. It is recommended to consider the establishment of safety surveillance plans, registries, retrospective studies and evaluation, etc. These activities should include clear communications and risk mitigation plans, educational activities, and promotion of vaccination.

Lastly, the questions in section E provide a suggested framework to summarize the results of the evaluation and assessment of candidate vaccines used in pregnant and breast-feeding women, identify data gaps, and serve as a tool for generating hypotheses for further research and surveillance, as well as for developing vaccine implementation plans.

5. Conclusion

It is essential to include pregnant and breast-feeding women in studies assessing vaccines against emerging pathogens, as they are often at high-risk for severe disease and potential adverse maternal and neonatal outcomes. Their inclusion in studies is critical to generate robust pre-licensure data on vaccines. Data for pregnant and breast-feeding women should continue to be assessed in post-licensure surveillance and other evaluations, to help identify which candidate vaccines and which approved vaccines are safe and optimal for use in these special populations. Concerted efforts are needed to alleviate concerns that vaccines for emerging pathogens will be rushed to market without adequate safety evaluation in pregnant and breast-feeding women.

The key questions developed by the MIWG will be a valuable tool for researchers and other key stakeholders to assess the suitability of new vaccines for pregnant and breast-feeding women. When feasible, pregnant and breast-feeding women should be included in vaccine trials to help guide regulatory and policy recommendations at the time of licensure or shortly after. Post-approval (e.g., under emergency or compassionate use authorization) or continued post-licensure surveillance studies will be necessary to characterize the benefit-risk profile in larger populations of pregnant and breastfeeding women.

The purpose of this tool is to provide a template for researchers and decision makers to consider the relevant aspects necessary to support the use of a vaccine in pregnancy or post-partum, with all elements considered important, and therefore not prioritized or mandated. The use of this tool should not hinder the development of clinical trials in emergency situations, including in LMIC, where the availability of some data might be limited. Input from pertinent regulatory agencies should be sought throughout the process of evaluation and implementation of vaccines for pregnant and breast-feeding women.

Author contribution

All authors participated in the Maternal Immunization Working Groups, reviewed the drafts and validated the final manuscript for submission.

ICMJE criteria

All authors attest they meet the ICMJE criteria for authorship.

CRediT authorship contribution statement

Flor M. Munoz: Writing – review & editing, Writing – original draft, Funding acquisition. **Beate Kampmann:** Writing – review & editing, Writing – original draft. **Andy Stergachis:** Writing – review & editing, Writing – original draft. **Manu Chaudhary:** Writing – review & editing,

Table 1

Key questions for the evaluation of candidate vaccines for emergent pathogen for pregnant and breast-feeding women: What is the evidence that pregnant and breast-feeding women need to be immunized against this pathogen?.

Section A. Key questions about the pathogen, disease, and pregnancy

A1 What is known about the risk in pregnant and non-pregnant women of child-bearing age

- A1.1 Are pregnant women at greater risk of infection-related complications than non-pregnant women of child-bearing age?
- A1.2 What are the clinical manifestations of disease in pregnant women?
- A1.3 Are the clinical manifestations similar to those in non-pregnant women of child-bearing age?
- A1.4 Are pregnant women at greater risk of severe disease (e.g. intensive care admission, death) than non-pregnant women and the general population?
- A1.5 Is the hospitalization rate higher in pregnant women compared with non-pregnant women and the general population?*
- A1.6 Is the intensive care admission rate higher in pregnant women compared with non-pregnant women and the general population?*
- A1.7 Is the risk of death higher in pregnant women than in non-pregnant women of child-bearing age and the general population of the same age?
- A1.8 Are there any disease effects or complications that are specific to pregnant women?
- A1.9 Is the risk of infection higher during a specific gestational trimester?
- A1.10 Is the risk of severe disease higher during a specific gestational trimester?
- A1.11 Is the risk of maternal death higher during a specific gestational trimester?
- A1.12 Are there known maternal factors or underlying medical conditions that increase the risk of infection, severe disease, or death?
- A1.13 What factors or underlying medical conditions increase the risk of infection, severe disease, or death during pregnancy?

A2. What is known about treatment for pregnant women?

- A2.1 Have pregnant women been included in clinical trials of treatments and vaccines for this disease?
- A2.2 What are other potential effects of infection and disease in pregnancy?
- A2.3 Are there specific, safe and effective treatments available for pregnant women?
- A2.4 What is the efficacy of existing treatments in pregnant women?

A3. What is known about the effect of the pathogen on pregnancy and obstetric outcomes

- A3.1 What are the adverse obstetric outcomes associated with maternal infection and disease?
- A3.2 What is the risk of preterm labor in infected women compared with non-infected women?
- A3.3 What is the risk of preterm delivery in infected women compared with non-infected women?
- A3.4 What is the rate of caesarean deliveries in infected women compared with non-infected women?
- A3.5 What are the indications for caesarean delivery in infected women?
- A3.6 What are the risks for specific maternal obstetric complications associated with infection and disease during pregnancy, including:
 - A3.6.1 Hypertension disorders, eclampsia, preeclampsia?
 - A3.6.2 Gestational diabetes?
 - A3.6.3 Antenatal and perinatal bleeding?
 - A3.6.4 Chorioamnionitis?
 - A3.6.5 Maternal infection and sepsis?
 - A3.6.6 Post-abortion and postpartum endometritis?

A4. Is there any evidence for vertical transmission of the pathogen and natural immunity?

- A4.1 Describe any evidence for vertical transmission via the placenta?
- A4.2 Describe any evidence for vertical transmission via breastmilk?
- A4.3 Is there evidence of placental infection?
 - A4.3.1 If yes, what are the mechanisms of placental infection?
- A4.4 Is there evidence of transplacental transfer of immunity after natural infection?
 - A4.4.1 If yes, during which trimester is the highest level of antibody transfer?
- A4.5 Is there evidence of transfer of immunity via breast milk after natural infection?

A5. Effects of maternal infection on the fetus

- A5.1 Does fetal infection occur?
 - A5.2 What is the risk of fetal infection?
 - A5.2.1 What is the risk of fetal infection by trimester of gestation?
 - A5.2.2 Is there evidence of teratogenicity or congenital malformations from infection?
- A5.3 What is the risk of teratogenicity?
- A5.4 Is there a risk of fetal loss?
 - A5.5.1 Does the risk of fetal loss vary by gestational trimester?
- A5.6.2 What is the risk of spontaneous abortion or miscarriage?
- A5.7.3 What is the risk of stillbirth?
- A5.8 What is the risk of intrauterine growth restriction?
- A5.9 Are there other fetal effects or risks associated with maternal infection with the pathogen?

A6 Effects of maternal infection on neonates and infants

- A6.1 What is the risk of prematurity following maternal infection?
- A6.2 What is the risk of neonatal infection?
- A6.3 What is the mechanism of transmission of neonatal infection from mother to infant?
- A6.4 What are the clinical manifestations of neonatal infection?
- A6.5 What is the risk of severe neonatal disease?
- A6.6 What is the risk of neonatal death?
- A6.7 What are the risks of neonatal sepsis, meningitis and other infections?
- A6.8 What are the risks of infection, disease and death in the first six months of life?
- A6.9 What are the risks of infection, disease and death in the first year of life?

A7 Post-partum and breast-feeding women:

- A7.1 Are post-partum and breast-feeding women at greater risk of infection?
- A7.2 What are the infection rates in post-partum and breast-feeding women compared with non-pregnant women and non-breast-feeding post-partum women?
- A7.3 Are post-partum and breast-feeding women at greater risk of severe disease compared with non-pregnant women and non-breast-feeding post-partum women?
- A7.4 Is the hospitalization rate higher in post-partum and breast-feeding women compared with non-pregnant women and non-breast-feeding women?
- A7.5 Is the rate of intensive care admission greater in post-partum and breast-feeding women with infection compared to non-pregnant and non-breast-feeding post-partum women?
- A7.6 Is the risk of maternal death during post-partum period greater than in the non-pregnant population?
- A7.7 Is the risk of maternal death greater in breast-feeding women than non-breast-feeding women?
- A7.8 Are there complications specific to post-partum and breast-feeding women?
- A7.9 Are there available antiviral or other specific therapies for post-partum and breast-feeding women?
- A7.10 What is the efficacy of available treatments in post-partum and breast-feeding women?
- A7.11 Are post-partum and breast-feeding women included in clinical trials of treatments and vaccines?

Section B. Key questions about specific vaccine platforms and components

B1 What safety data are available to show that use of the vaccine in pregnancy and breast-feeding is safe?

B2 Vaccine name and manufacturer

B3 Vaccine construct or platform (use BRAVATO tables in Appendix II for specific non-pregnancy questions)

Protein or subunit (Appendix II.A) [43]

Nucleic acid (Appendix II.B) [44]

Viral vector (Appendix II.C) [45]

Live attenuated vaccines (Appendix II.D) [46]

Inactivated vaccines (Appendix II.E) [47]

B4 General and pre-clinical toxicology studies on vaccine construct and components

B4.1 Are there any safety data from pregnant and non-pregnant animal models for the vaccine construct or platform or any of the vaccine components?

B4.2 Have developmental and reproductive toxicity studies (DART) been conducted?

B4.2.1 If, yes, describe these studies and indicate which components of the vaccine were evaluated (complete vaccine construct or specific components)

B4.2.2 If yes, describe any developmental or reproductive toxicities identified?

B4.2.3 Were any other pregnancy-related issues associated with any of the specific components of this vaccine identified in animal studies?

B4.2.4 If yes, describe these issues

B4.3 Are there any placental biology data for this vaccine construct or platform or any of the components? If yes, describe

B5 Vaccine construct- or platform-specific questions

B5.1 Are there any pregnancy-related issues in clinical studies associated with the vaccine specific construct or platform or any of the components? If yes, describe

B6 Antigen, adjuvant and other components-specific questions

B6.1 Were pregnancy-related issues associated with the antigen, adjuvant or other specific components of this vaccine in clinical studies? If yes, describe.

B7 Construct or platform-specific data in humans: non-pregnant population

B7.1 Are there any safety data for licensed vaccines that use this specific construct or platform in non-pregnant populations? If yes, describe

B7.2 Are there any safety data from clinical trials using this specific construct or platform in non-pregnant populations, even if not licensed? B7.2.1 If yes, describe

B8 Construct or platform-specific efficacy and effectiveness data in humans: non-pregnant population

B8.1 Describe the mechanism or correlates of protection

B8.2 Are there any efficacy data from clinical trials using this specific construct or platform in non-pregnant populations? If yes, describe

B8.3 Are there any efficacy or effectiveness data for licensed vaccines that use this specific construct or platform in non-pregnant populations? B8.3.1 If yes, describe

B9 Construct or platform-specific safety data in humans: pregnant populations

B9.1 Are there any safety data for pregnant women in early clinical studies using this specific construct or platform, even if not licensed?

B9.2 Are there any safety data for pregnant women who were inadvertently exposed, during clinical trials or not?

B9.3 Are there any safety data for breast-feeding women?

B9.4 Are there any pregnancy-related safety issues associated with this specific construct or platform?

B10 Construct or platform-specific efficacy/effectiveness data in humans: pregnant population

B10.1 Describe the mechanisms or correlates of protection

B10.2 Are there any efficacy or effectiveness data from early clinical trials or pharmacokinetic or pharmacodynamic studies using this specific construct or platform, even if not licensed?

B10.2 Are there any efficacy data for pregnant women exposed inadvertently or intentionally or real-world effectiveness data for pregnant women receiving the vaccine post-licensure?

B10.3 Are there any efficacy or effectiveness data for breast-feeding women?

B10.4 Are there any pregnancy-specific efficacy issues associated with this specific construct or platform? If yes, describe.

B11 Other vaccine components: pregnancy-specific questions

B11.1 What is known about the delivery system (e.g., lipid nanoparticles) or other components of the vaccine in pregnancy?

B11.2 What is known about transplacental transfer of these delivery systems and components?

B11.3 What is known about the permanence of vaccine delivery or other components in tissues?

B12 Vaccine storage, delivery and administration characteristics

B12.1 Is vaccine use in the context of antenatal care feasible?

B12.1.1 Describe vaccine storage requirements in relation to antenatal care needs/settings

B12.1.2 Describe vaccine administration requirements

B12.1.3 Describe the number of doses needed and interval between doses

B12.1.4 Describe specific considerations for vaccine administration in relation to other vaccines that are given during pregnancy (e.g., influenza, tetanus, pertussis).

B12.1.5 Describe specific considerations for vaccine administration in relation to medications or other vaccines that are or could be given during pregnancy.

Section C. Key questions about the development and planning for all candidate vaccines (regardless of construct or platform) for pregnant and breast-feeding women and their exposed offspring

C1 Pre-clinical pregnancy data

C1.1 Are results of DART studies available or required?

C1.1.1 DART study completion dates or expected completion date

C1.1.2 Findings of DART studies (also see questions in Section B.3)

C2 Clinical development status and plans for the vaccine in non-pregnant populations

C2.1 Target populations in clinical studies

C2.1.1 Planned studies: planned total enrolment (answer for each: phase 1, phase 2, phase 3)

C2.1.2 Ongoing studies: planned total enrolment (answer for each: phase 1, phase 2, phase 3)

C2.1.3 Completed studies: total enrolment (answer for each: phase 1, phase 2, phase 3)

C2.2 Location of clinical studies

C2.2.1 Where are(were) the clinical studies conducted? List all countries

C2.2.2 Will studies be conducted in high-income countries (HICs) and low- to middle-income countries (LMICs) countries simultaneously?

C2.2.3 Will the approved vaccine be distributed in HICs and LMICs countries simultaneously?

C2.2.4 Will vaccine be distributed in epidemic or endemic areas?

C3 Safety data for non-pregnant populations

C3.1 Vaccine reactogenicity (after each dose)

C3.1.1 Proportion of individuals with fever, frequency and duration of fever after each immunization, need for pre-emptive or symptomatic treatment

C3.2 Adverse events following immunization (AEFIs)

C3.3 Serious adverse events (SAEs)

(continued on next page)

Table 1 (continued)

-
- C3.4 Adverse events of special interest (AESIs)
 - C3.5 Duration of safety follow up
 - C4 Immunogenicity data from non-pregnant populations**
 - C4.1 Is there an accepted correlate of protection? (include assessment of data quality)
 - C4.2 Antibody responses (include assessment of data quality)
 - C4.3 Cell-mediated immunity (CMI) (Th1 vs. Th2) responses (include assessment of data quality)
 - C4.4 Duration of immunity (include assessment of data quality)
 - C4.4.1 How is immunity defined? (antibodies? CMI? other?)
 - C4.4.2 What is the duration of follow up and protection?
 - C4.5 Is there a need for repeated immunizations?
 - C5 What efficacy data are available for non-pregnant population?**
 - C5.1 What are the efficacy outcomes? (e.g., protection against infection? symptomatic infection? severe disease? death?)
 - C5.2 Efficacy after partial vaccination?
 - C5.3 Efficacy after complete vaccination?
 - C6 Inadvertent exposure during pregnancy in clinical studies in non-pregnant populations**
 - C6.1 Is there a plan to capture data for women who become pregnant during clinical trials? Describe plan or protocol, as well as the mechanism for reporting outcomes
 - C6.2 Will women who become pregnant during the clinical trial have the option to remain in the trial? Yes/no: explain rationale and plan
 - C6.3 What immunogenicity data are being/will be collected from women who become pregnant during the clinical trial?
 - 6.3.1 Describe immunogenicity data, if any, collected to date
 - C6.4 What safety data are being/will be collected from women who become pregnant during the clinical trial?
 - C6.4.1 Describe any safety data collected to date. Include data collection forms and mechanism for reporting outcomes
 - C6.5 What efficacy data are being/will be collected from women who become pregnant during the clinical studies?
 - C6.5.1 Describe any efficacy data collected to date.
 - C6.6 What is the duration of follow-up for women who become pregnant in clinical trials? (include length and intervals of follow-up)
 - 6.6.1 Describe follow-up data, if any, collected to date
 - C6.7 What is the plan for collection of data from women in post-partum period?
 - 6.7.1 Describe post-partum data, if any, collected to date.
 - C6.8 What is the plan for follow up and collection of safety and efficacy data in the infants born after women became pregnant in clinical trials?
 - C6.8.1 Describe any infant data collected to date
 - C7 Communication plan for inadvertent exposures in pregnant women**
 - C7.1 What is the plan for analyzing and sharing data about inadvertent pregnancy exposure to vaccine during clinical trials?
 - C8 Inclusion of pregnant women in clinical trials**
 - C8.1 Is there a plan to enroll pregnant women in clinical studies?
 - C8.1.1 If no, what is the justification for exclusion?
 - C8.2 What is the plan for recruitment of pregnant women into clinical studies? Describe
 - C8.3 What immunogenicity data are being/will be collected from pregnant women in clinical studies?
 - C8.3.1 Describe any immunogenicity data collected to date
 - C8.4 What safety data are being or will be collected from pregnant women in clinical studies?
 - C8.4.1 Describe any safety data collected to date
 - C8.5 What efficacy data are being/will be collected from pregnant women in clinical studies?
 - C8.5.1 Describe any efficacy data collected to date.
 - C8.6 Is there a plan to collect data from women in the post-partum period?
 - C8.6.1 If yes, describe
 - C8.6.2 If no, explain the justification
 - C8.7 Is there a plan for the collection and testing of breastmilk from post-partum women who were enrolled in clinical studies while pregnant?
 - C8.7.1 If yes, describe
 - C8.7.2 If no, what is the justification
 - C8.8 Is there a plan for the collection and follow up of infants of women enrolled in clinical studies while pregnant?
 - C8.8.1 If yes, describe the protocol, safety, immunogenicity, efficacy data being collected, as well as duration of follow up
 - C9 Communication plan for pregnancy exposures in clinical studies**
 - C9.1 What is the plan for analyzing and sharing information about vaccine administration to pregnant women enrolled in clinical trials?
 - C10 Plan for inclusion of breast-feeding women in clinical trials**
 - C10.1 Is there a plan to include breast-feeding women in clinical trials?
 - C10.1.1 If yes, describe the plan
 - C10.1.2 If no, what is the justification for their exclusion?
 - C10.2 Is there a plan for the collection and testing of breastmilk from breast-feeding women enrolled in clinical studies? (also see questions in Section C.16)
 - C11 Fetuses, neonates and infants**
 - C11.1 What is the plan for collection of data from fetuses of exposed pregnant women enrolled in clinical studies?
 - C11.2 What is the plan for capture of data from neonates whose mothers were exposed in clinical studies?
 - C11.3 What is the plan for follow-up of infants whose mothers were exposed in clinical studies? Describe, including intervals and duration
 - C11.4 Will infant antibody titers be measured following birth to assess levels and duration after exposure? (also see questions in Section C17)
 - C12 Vaccine approval for pregnant women**
 - C12.1 What additional data is needed for vaccine approval for pregnant women?
 - C13 Pregnancy-specific safety questions**
 - C13.1 What reactogenicity is acceptable in pregnancy?
 - C13.1.1 Percentages of individuals with fever, severity of fever, duration of fever
 - C13.1.2 Local reactogenicity
 - C13.1.3 Systemic reactogenicity
 - C13.1.4 Other
 - C14 Timing of vaccination during pregnancy**
 - C14.1 What should be the preferred timing of vaccination during pregnancy and why?
 - C14.2 Is the dosing schedule amenable to administration during pregnancy?
 - C14.3 Can the full dose series be completed during pregnancy?
 - C14.4 Can the dose series include pre- or post-pregnancy administration?

(continued on next page)

Table 1 (continued)

- C14.5 Can the dose series be administered with other vaccines given during pregnancy?
 C14.5.1 If, yes, what are the considerations for concomitant vaccination?
- C15. Adverse events in pregnant women**
- C15.1 What adverse events following immunization (AEFIs) should be monitored?
 C15.1.1 Maternal
 C15.1.2 Obstetric
 C15.1.3 Fetal, neonatal
- C15.2 What outcomes of special interest (AESIs) should be monitored?
- C15.3 What is the risk of vaccine-associated enhanced disease (VAED)?
- C15.4 What is the risk of breakthrough infection and post-infection complications?
- C15.5 What is the risk for obstetric complications?
- C15.6 What is the risk for neonatal complications?
 C15.6.1 Are AEs in infant associated with gestational age and timing of exposure?
- C16. Breast-feeding-specific questions**
- C16.1 Is there a plan to test antibody concentration in breastmilk? Yes/No? If yes, describe
- C16.2 Is there a plan to determine the effect of vaccine on breast-feeding infants? Yes/No? If yes, describe
- C16.3 Describe any plans for adverse event evaluation in breast-feeding women
- C16.4 What AEFIs should be monitored in breastfed infants?
- C16.5 What outcomes of special interest (AESIs) should be monitored in breastfed infants?
- C17. Fetus- infant-specific questions**
- C17.1 Is there a plan to determine if infant seroprotection is achieved following maternal immunization? Yes/No. If no, why? If yes, describe
- C17.2 What is the ratio of maternal-to-infant antibody at delivery? (transplacental antibody passage)
- C17.3 What is the duration of maternally-derived antibody?
- C17.4 What is the effect of maternal antibody on natural disease in the infants?
- C18. Adverse events in infants**
- C18.1 What AEFIs should be monitored in infants?
- C18.2 What AESIs should be monitored in infants?
- C19. Follow-up infants of after birth**
- C19.1 How long should infants exposed in utero be followed up after birth?

Section D. Key questions for post-licensure safety evaluation of vaccine use during pregnancy

D1 Who has access to detailed and timely post-licensure safety surveillance data?**D2 General safety surveillance**

- D2.1 What study designs should be considered for the post-licensure assessment of vaccine safety, in addition to routine surveillance?
- D2.2 Are hospital-based systems or sentinel site-based approaches for safety surveillance feasible?
- D2.3 Is it feasible to do prospective safety studies of vaccinated pregnant and breast-feeding women?
- D2.4 Is it feasible to do retrospective safety studies of vaccinated pregnant and breast-feeding women?
- D2.5 How should passive safety surveillance systems be strengthened to improve signal detection?
- D2.6 What active safety surveillance approaches should be used to identify AESIs in LMICs?

D3 Safety data for pregnant women exposed to approved or licensed vaccine

- D3.1 Was the vaccination recommended by a healthcare provider?
- D3.2 Details of vaccine administration: date, platform, construct, adjuvant (See sections B and C)
 D3.2.1 In what setting was the vaccine administered?
- D3.3 Are there any known adverse events associated with use of the platform, construct, or adjuvant? If yes, give details
- D3.4 When did vaccine exposure occur during pregnancy?
- D3.5 Can maternal data be linked to the offspring's data and any adverse outcomes in the newborn or neonate?
- D3.6 Can maternal data be linked to the offspring's data and any adverse outcomes in the infant (12 months after birth)?

D4 AEFIs and AESIs

- D4.1 What pregnancy-specific or neonate-specific AEFIs or AESIs should be monitored?
- D4.2 What safety outcomes or potential AEFIs were identified during pre-clinical studies that should be assessed in the post-licensure period?
- D4.3 Were any pregnancy-related safety signals identified during previous vaccine clinical trials, either those that recruited pregnant women, or those monitoring inadvertently exposed pregnant women?
- D4.4 What patient factors are important for the study population?
 D4.4.1 Examples: age; current or prior infections; HIV status; obesity; hypertension; diabetes; alcohol abuse; substance abuse; singleton versus multiple pregnancy; prior pregnancy complications; other factors?
- D4.4.2 Is prior infection a factor? Or an exclusion criterion?
- D4.4.3 Other factors?

D5 Pregnancy registries

- D5.1 Is/was there a pregnancy registry from prior use of candidate vaccine for other indications?
- D5.2 Is a post-licensure pregnancy registry in the development plan?
- D5.3 Will /was a pregnancy registry mandated by regulatory agencies?
- D5.4 Will the manufacturer be able to set up a pregnancy registry in LMICs?
- D5.5 Are there plans for the use of standardized and harmonized methods for a pregnancy registry to allow data pooling?

D6 Active post-licensure studies

- D6.1 Are pharmacoepidemiology studies planned or established to identify or evaluate potential risks during the post-licensure period?
- D6.2 Are there any other ongoing studies following-up on pregnant or breast-feeding women and their infants for 6 to 12 months post-exposure to vaccination?
- D6.3 What other safety activities are/were recommended by regulatory authorities or WHO?

D7 Communication of safety findings

- D7.1 How will the findings of any safety studies be communicated to pregnant women?
- D7.2 How will the findings of any safety studies be communicated to the public?
- D7.3 How will the findings of any safety studies be communicated to other key stakeholders?
- D7.4 Do the communication plans include advice on how to deal with misinformation and hesitancy due to vaccine safety concerns?

D8 Vaccine uptake

- D8.1 What is the anticipated or known acceptance of the vaccine in the general population?
- D8.2 What is the anticipated or known acceptance of vaccines in general in pregnant women?

(continued on next page)

Table 1 (continued)

- D8.3 What is the anticipated or known acceptance of the specific vaccine in pregnant women?
 D8.4 Will pregnant women choose to participate in vaccine clinical trials?
 D8.5 Will pregnant women choose to participate in post-licensure vaccine studies?

Section E. Summary of the evaluation of the candidate vaccine for use in pregnant and breast-feeding women

E1 Key criteria to suggest vaccine for:

- E1.1 Pregnant women
 E1.2 Breast-feeding women

E2 Key criteria to reject vaccine for:

- E2.1 Pregnant women
 E2.2 Breast-feeding women

E3 Key considerations for proceeding with evaluation of a vaccine for:

- E3.1 Pregnant women
 E3.2 Breast-feeding women

E4 What safety data are needed for inclusion of pregnant women in clinical studies?**E5 What efficacy data are needed for inclusion of pregnant women in clinical studies?****E6 What are the identified data gaps?****E7 In which vaccine development phase should pregnant women be included?****E8 What is the optimal timing for vaccination during pregnancy?****E9 Has the communication plan been finalized and accepted by all stakeholders?****E9.1 Has the communication plan been implemented?**

* It may be difficult to identify if the reason for hospitalization was for the pregnancy or for the illness.

** The threshold for admission to intensive care is likely to be lower for pregnant women than non-pregnant women.

Writing – original draft. **Clare L. Cutland:** Writing – review & editing, Writing – original draft. **Asma Khalil:** Writing – review & editing, Writing – original draft. **Angela Gentile:** Writing – review & editing, Writing – original draft. **Christine E. Jones:** Writing – review & editing, Writing – original draft. **Helen Marshall:** Writing – review & editing, Writing – original draft. **Esperanca Sevens:** Writing – review & editing, Writing – original draft. **Delese Mimi Darko:** Writing – review & editing, Writing – original draft. **Geeta Swamy:** Writing – review & editing, Writing – original draft. **Terri B. Hyde:** Writing – review & editing, Writing – original draft. **Gerald Voss:** Writing – review & editing, Writing – original draft. **Ajoke Sobanjo-Ter Muelen:** Writing – review & editing, Writing – original draft.

Disclaimer

The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the COVAX-CEPI and CEPI-SPEAC Maternal Immunization Working Groups. They do not necessarily represent the official positions of any participant's organization (e.g., government, university, or corporations) and should not be construed to represent any Agency determination or policy.

Funding

This work was supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to the Safety Platform for Emergency vAccines (SPEAC) Project.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Flor M. Munoz reports a relationship with Pfizer that includes: consulting or advisory and funding grants. Flor M. Munoz reports a relationship with Moderna that includes: consulting or advisory. Flor M. Munoz

reports a relationship with Meissa Vaccines that includes: consulting or advisory. Flor M. Munoz reports a relationship with National Foundation of Infectious Diseases that includes: board membership. Clare L. Cutland reports a relationship with Bill & Melinda Gates Foundation that includes: funding grants. Clare L. Cutland reports a relationship with Pfizer that includes: funding grants. Clare L. Cutland reports a relationship with German Society for International Cooperation (GIZ) GmbH that includes: funding grants. Helen Marshall reports a relationship with Sanofi Pasteur that includes: funding grants. Helen Marshall reports a relationship with Seqirus that includes: funding grants. Helen Marshall reports a relationship with Moderna that includes: funding grants. Helen Marshall reports a relationship with ILiAD Biotechnologies that includes: funding grants. Geeta Swamy reports a relationship with Pfizer that includes: consulting or advisory. Geeta Swamy reports a relationship with GSK that includes: consulting or advisory and speaking and lecture fees. Geeta Swamy reports a relationship with Moderna that includes: consulting or advisory. Geeta Swamy reports a relationship with Sanofi Pasteur that includes: speaking and lecture fees. Corresponding author is an associate editor for Vaccine and a member of the ACOG Immunization Expert Group-FMM Co-author was a member of the Brighton Collaboration Scientific Committee 2018–2023-CLC Co-author is a contributor to UpToDate on listeria in pregnancy and a Medscape educational contributor on congenital CMV - GS. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors would like to acknowledge medical writing and editorial services provided by Margaret Haugh, PhD, MediCom Consult (France) funded by CEPI/SPEAC, and the project management support provided by BMGF and by Izidora Skracic, MSc, and Maria de la Paz Aguirre, MSc, WeDo Project Intelligence Made Easy (Spain), also funded by CEPI/SPEAC.

Appendix A. Appendix

A.1. Members and workstreams of the COVAX-CEPI maternal immunization working group

Co-chairs: Flor Muñoz, Ajoke Sobanjo-ter Meulen					
Work Stream 1 PRODUCT MAPPING		Work Stream 2 PRE-CLINICAL / CLINICAL		Work Stream 3 VACCINE SAFETY	
Emily Erbeling (LEAD)	Director, Division of Microbiology and Infectious Diseases NIH – ACTIV; US	Beate Kampmann (LEAD)	Professor of Pediatric Infection & Immunity; Director of the Vaccine Centre, London School of Health and Tropical Medicine, UK	Stephen Anderson (LEAD)	Director, Office of Biostatistics and Epidemiology, CBER/WHO-GAVCS, US
Ajoke Sobanjo-ter Meulen	Senior Program Officer, Bill & Melinda Gates Foundation, US	Flor Muñoz	Associate Professor, Pediatrics-Infectious Disease, Baylor College of Medicine, US	Andrew Stergachis (LEAD)	Professor, Global Health; Professor, Pharmacy, Director, Global Medicines Program University of Washington, US
Karin Bok	Senior Advisor Vaccine Development, VRC, NIAID, NIH; US	Geeta Swamy	Associate Professor of Obstetrics and Gynecology, Duke University School of Medicine, US	Steve Black Delese Mimi Darko Christine Guillard	CEPI-SPEAC, US Chief Executive Office, Ghana Food and Drugs Authority, Ghana Global Vaccine Safety Initiative, WHO
Anh Wartel	Associate Director General of Clinical Development, IVI, South Korea	Clare L. Cutland	Lecturer, University of the Witwatersrand, South Africa	Esperança Sevene	Associate Professor, Universidade Eduardo Mondlane, Mozambique
Angela Gentile	Head, Department of Epidemiology, Ricardo Gutiérrez Children's Hospital; Argentina	Asma Khalil	Professor, Consultant obstetrician at St George's Hospital, London, UK		
Gerald Voss	Scientific Director of the TuBerculosis Vaccine Initiative/ CEPI, Belgium	Helen Marshall	Clinical Research Director and Prof Vaccinology, Women's and Children's Health Network and The University of Adelaide, Australia		
Johan Vekemans	SARS-CoV-2 vaccine Global Clinical Head, AstraZeneca, Belgium	Chrissie Jones	Associate Professor in Pediatric Infectious Diseases and Immunology, University of Southampton, UK		
Titilope Odeyebo	CDC, US ACOG, IIFPHEWG	Sylvanus Okogbenin Judith Absalon	Professor, Consultant Obstetrician, Irrua Specialist Teaching Hospital, Nigeria Senior Director, Vaccines Clinical Research, Pfizer, US		
Cross-cutting advisors					
Marion Gruber (Regulatory)	Director, Center for Biologics Evaluation and Research (CBER) FDA; US	Helen Rees (Regulatory)	Professor, Wits Reproductive Health and HIV Institute, Board Chair SAHPRA; South Africa	Daniel Brasseur (Regulatory)/ CEPI	Former CHMP-PDCO-VWP chair at EMA; CEPI consultant; EU
Ruth Karron (Ethics)	Professor, Johns Hopkins Bloomberg School of Public Health; US	Carleigh Krubiner (Ethics)	Policy Fellow, Center for Global Development, Johns Hopkins Univ; US		

A.2. Members of the CEPI-SPEAC maternal immunization working group

Name and Credentials	Affiliation
Flor M. Muñoz, Associate Professor, Pediatrics-Infectious Disease	Baylor College of Medicine, Houston, TX US
Manu Chaudhary, Pediatric Infectious Diseases Consultant, Clinical Educator, Infection Control Officer	Rainbow Children's Hospital, Bangalore, Karnataka, India
Magdalena Babinska, Consultant	World Health Organization, Geneva, Switzerland
Mercedes Bonet, Medical Officer	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
Clare L. Cutland, Scientific coordinator	Wits African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Darko Mimi Delese, Chief Executive of the Food and Drugs Authority	Ghana Food and Drugs Authority, Ghana
Sascha Ellington, Epidemiologist and Lead, Influenza Prevention and Control Team	US CDC, Atlanta, GE, US
Darcie Everett, Medical Officer. US Food and Drug Administration	US CDC, Atlanta, GE, US
Lee Fairlie, Associate Professor, Director Maternal and Child Health	Wits RHL, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Angela Gentile, Professor, Epidemiology Department Head	Hospital de Niños, R Gutierrez, Universidad de Buenos Aires, Argentina
Sami Gottlieb, Medical Officer	WHO, Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
Terri B. Hyde, Medical Epidemiologist, Vaccine Introduction Team Lead	US CDC, Atlanta, GE, US
Christine E. Jones, Assoc Professor of Pediatric Infection at the University of Southampton	University of Southampton, Southampton, UK
Beate Kampmann, Director of the Centre for Global Health	Charité Universitätsmedizin Berlin, Germany
Ruth Karron, Professor, Bloomberg School of Public Health	Center for Immunization Research, US

(continued on next page)

(continued)

Name and Credentials	Affiliation
Asma Khalil Professor of Obstetrics and Maternal-Fetal Medicine	St George's University Hospital, University of London, London UK
Helen Marshall, Clinical Research Director and Prof Vaccinology,	Women's and Children's Health Network and The University of Adelaide, Australia
Dana M. Meaney Delman, Chief, Infant Outcomes Monitoring	US CDC, Atlanta, GE, US
Research and Prevention Branch	
Samantha Olson, Epidemiologist	US CDC, Atlanta, GE, US
Proma Paul, TLSI Coordinator at King's College London	LSHTM, University of London, London, UK
Anna Seale, Senior Program Officer	BMGF, US
Esperança Sevene, Associate Researcher and Assistant Professor	Department of Physiological Science, Clinical Pharmacology, Faculty of Medicine, Eduardo Mondlane University,
of Clinical Pharmacology	Maputo, Mozambique
Geeta Swamy, Professor of Obstetrics & Gynecology, Division of	Duke University School of Medicine, Durham, NC, US
Maternal-Fetal Medicine	
Andy Stergachis, Professor, Global Health, Professor Pharmacy,	University of Washington, Seattle, WA, US
Director Global Medicines Program	
Gerald Voss, Director of R&D programs	CEPI, US
Niranjan Bhat, Senior Medical Officer	PATH, Seattle, WA, US

Appendix B. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.vaccine.2025.127513>.

Data availability

No data was used for the research described in the article.

References

- [1] Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. *Stud Fam Plan* 2014;45:301–14. <https://doi.org/10.1111/j.1728-4465.2014.00393.x>.
- [2] Bismark M, Morris J, Thomas L, Loh E, Phelps G, Dickinson H. Reasons and remedies for under-representation of women in medical leadership roles: a qualitative study from Australia. *BMJ Open* 2015;5:e009384. <https://doi.org/10.1136/bmjopen-2015-009384>.
- [3] Mousa M, Boyle J, Skouteris H, Mullins AK, Currie G, Riach K, et al. Advancing women in healthcare leadership: a systematic review and meta-synthesis of multi-sector evidence on organisational interventions. *EclinicalMedicine* 2021;39:101084. <https://doi.org/10.1016/j.eclim.2021.101084>.
- [4] Cassells R, Duncan A. Gender equity insights 2019: Breaking through the glass ceiling: BCEC report. Bentley WA: Bankwest Curtin Economics Centre; 2019.
- [5] Magar V, Gerecke M, Dhillon I, Campbell J. Chapter 2: Women's contributions to sustainable development through work in health: Using a gender lens to advance a transformative 2030 agenda. In: Buchan J, Dhillon I, Campbell J, editors. *Health employment and economic growth: An evidence base*. Geneva: World Health Organization; 2017.
- [6] World Health Organization. Maternal, newborn, child and adolescent health and ageing. Data portal: Women of reproductive age (15–49 years) population (thousands). 2024. Last accessed 22 July. Available from, <https://platform.who.int/data/maternal-newborn-child-adolescent-ageing/indicator-explorer-new/MCA/women-of-reproductive-age>; 2024.
- [7] Academies National, of Science, Engineering and Medicine. In: Kahn B, Brown L, Foege W, Gayle H, editors. *Framework for equitable allocation of COVID-19 vaccine*. Washington (DC): National Academies Press (US); 2020 Oct 2. <https://doi.org/10.17226/25917>. PMID: 33026758.
- [8] Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–75. <https://doi.org/10.15585/mmwr.mm6925a1>.
- [9] Foeller ME, Ribeiro Carvalho, do Valle C, Foeller TM, Oladapo OT, Roos E, et al. Pregnancy and breastfeeding in the context of Ebola: a systematic review. *Lancet Infect Dis* 2020;20:e149–58. [https://doi.org/10.1016/s1473-3099\(20\)30194-8](https://doi.org/10.1016/s1473-3099(20)30194-8).
- [10] Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. *Am J Obstet Gynecol* 2012;207:S3–8. <https://doi.org/10.1016/j.ajog.2012.06.068>.
- [11] Centers for Disease Control and Prevention. CDC updates, expands list of people at risk of severe COVID-19 illness. 2020. Last accessed 2 August. Available from, <https://www.cdc.gov/media/releases/2020/p0625-update-expands-covid-19.html>; 2023.
- [12] Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1641–7. <https://doi.org/10.15585/mmwr.mm6944e3>.
- [13] Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320. <https://doi.org/10.1136/bmj.m3320>.
- [14] Lokken EM, Walker CL, Delaney S, Kachikis A, Kretzer NM, Erickson A, et al. Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington state. *Am J Obstet Gynecol* 2020;223. <https://doi.org/10.1016/j.ajog.2020.05.031>. 911.e1–e14.
- [15] Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). *Obstet Gynecol* 2021;137:571–80. <https://doi.org/10.1097/aog.0000000000004339>.
- [16] Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics-eight U.S. health care centers, March 1–May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1355–9. <https://doi.org/10.15585/mmwr.mm6938e2>.
- [17] DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization-United States, march 2020–September 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1640–5. <https://doi.org/10.15585/mmwr.mm7047e1>.
- [18] Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *Bmj* 2020;369:m2107. <https://doi.org/10.1136/bmj.m2107>.
- [19] McClymont E, Albert AY, Alton GD, Boucoiran I, Castillo E, Fell DB, et al. Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes. *JAMA* 2022;327:1983–91. <https://doi.org/10.1001/jama.2022.5906>.
- [20] Krubiner CB, Schwartz DA. Viral hemorrhagic fevers in pregnant women and the vaccine landscape: comparisons between yellow fever, Ebola, and Lassa fever. *Curr Trop Med Rep* 2019;6:186–96. <https://doi.org/10.1007/s40475-019-00194-x>.
- [21] Gajbhiye RK, Sawant MS, Kuppusamy P, Surve S, Pasi A, Prusty RK, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. *Int J Gynaecol Obstet* 2021;155:48–56. <https://doi.org/10.1002/ijgo.13793>.
- [22] World Health Organization. *Pandemic influenza risk management: A WHO guide to inform and harmonize national and international pandemic preparedness and response*. Geneva: World Health Organization; 2017.
- [23] World Health Organization. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Last accessed 3 August 2023; Available from, <https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination>; 2020.
- [24] Krubiner CB, Faden RR, Karron RA, Little MO, Lyster AD, Abramson JS, et al. Pregnant women & vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response. *Vaccine* 2021;39:85–120. <https://doi.org/10.1016/j.vaccine.2019.01.011>.
- [25] Long-term safety follow-up of participants exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo. *ClinicalTrials.gov* (web archive link), 12 December 2022; 2016. identifier: NCT02661464. Updated 12 December 2022. Last accessed 3 August 2023; Available from, <https://classic.clinicaltrials.gov/ct2/show/NCT02661464>.
- [26] A study of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in healthy pregnant women (INGABO). *ClinicalTrials.gov* (web archive link), 17 May 2023; 2020. identifier: NCT04556526. Updated 17 May 2023. Last accessed 3 August 2023; Available from, <https://classic.clinicaltrials.gov/ct2/show/NCT04556526>.
- [27] American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric–gynecologic care. Last accessed 3 August 2023; Available from, <https://www.acog.org/clinical/clinical-guidance/practice-advisor>

- y/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care; 2023.
- [28] John Hopkins Berman Institute of Bioethics. PREVENT (Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies). Last accessed 3 August 2023; Available from: <https://bioethics.jhu.edu/research-and-outreach/projects/prevent/>; 2023.
- [29] Academies National, of Sciences E, Medicine. Framework for equitable allocation of COVID-19 vaccine. Washington, DC: The National Academies Press; 2020.
- [30] World Health Organization. WHO target product profiles for COVID-19 vaccines. Revised version April. 2022. p. 2022. Last accessed 3 August 2023; Available from: <https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines>.
- [31] Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. *JAMA* 2021;326:728–35. <https://doi.org/10.1001/jama.2021.11035>.
- [32] The Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for biomedical research involving human subjects. Last accessed 5 August 2023; Available from: <https://cioms.ch/publications/product/international-ethical-guidelines-for-biomedical-research-involving-human-subjects-2/>; 2002.
- [33] UNAIDS/WHO. Ethical considerations in biomedical HIV prevention trials. Last accessed 5 August 2023; Available from: https://data.unaids.org/pub/monograph/2007/jc1349_ethics_2_11_07_en.pdf; 2007.
- [34] US FDA. Pregnant women: Scientific and ethical considerations for inclusion in clinical trials. Last accessed 5 August 2023; Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnant-women-scientific-and-ethical-considerations-inclusion-clinical-trials>; 2018.
- [35] Kinnunen TI, Aittasalo M, Koponen P, Ojala K, Mansikkamäki K, Weiderpass E, et al. Feasibility of a controlled trial aiming to prevent excessive pregnancy-related weight gain in primary health care. *BMC Pregnancy Childbirth* 2008;8:37. <https://doi.org/10.1186/1471-2393-8-37>.
- [36] Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol* 2015;3:767–77. [https://doi.org/10.1016/s2213-8587\(15\)00227-2](https://doi.org/10.1016/s2213-8587(15)00227-2).
- [37] Poston L, Briley AL, Barr S, Bell R, Croker H, Coxon K, et al. Developing a complex intervention for diet and activity behaviour change in obese pregnant women (the UPBEAT trial); assessment of behavioural change and process evaluation in a pilot randomised controlled trial. *BMC Pregnancy Childbirth* 2013;13:148. <https://doi.org/10.1186/1471-2393-13-148>.
- [38] Palmer S, Pudwell J, Smith GN, Reid RL. Optimizing participation of pregnant women in clinical trials: factors influencing decisions about participation in medication and vaccine trials. *J Obstet Gynaecol Can* 2016;38:945–54. <https://doi.org/10.1016/j.jogc.2016.04.100>.
- [39] Sutton EF, Cain LE, Vallo PM, Redman LM. Strategies for successful recruitment of pregnant patients into clinical trials. *Obstet Gynecol* 2017;129:554–9. <https://doi.org/10.1097/aog.0000000000001900>.
- [40] US FDA. Development and licensure of vaccines to prevent COVID-19 guidance for industry. Last accessed 5 August 2023; Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19>; 2020.
- [41] World Health Organization. The Access to COVID-19 Tools (ACT). Accelerator 2023. Last accessed 5 August 2023; Available from: <https://www.who.int/initiatives/act-accelerator>.
- [42] Brighton Collaboration. Benefit-risk assessment of Vaccines by Technology (BRAVATO; ex-V3SWG). Last accessed 5 August 2023; Available from: <https://brighcollaboration.us/bravato/>; 2020.
- [43] Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, et al. The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. *Vaccine* 2020;38:5734–9. <https://doi.org/10.1016/j.vaccine.2020.06.044>.
- [44] Kim D, Robertson JS, Excler JL, Condit RC, Fast PE, Gurwith M, et al. The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. *Vaccine* 2020;38:5556–61. <https://doi.org/10.1016/j.vaccine.2020.06.017>.
- [45] Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, et al. The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. *Vaccine* 2020;38:7708–15. <https://doi.org/10.1016/j.vaccine.2020.08.009>.
- [46] Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, et al. Brighton collaboration viral vector vaccines safety working group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. *Vaccine* 2020;38:7702–7. <https://doi.org/10.1016/j.vaccine.2020.09.042>.
- [47] Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, et al. The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. *Vaccine* 2020;38:6184–9. <https://doi.org/10.1016/j.vaccine.2020.07.028>.